We tap into an unexplored area of preferential crystallization, being the first to develop simultaneous chiral resolution of two racemic compounds by preferential cocrystallization. We highlight how the two racemic compounds RS-mandelic acid (MAN) and RS-etiracetam (ETI) can be combined together as enantiospecific R-MAN⋅R-ETI and S-MAN⋅S-ETI cocrystals forming a stable conglomerate system and subsequently develop a cyclic preferential crystallization allowing to simultaneous resolve both compounds. The developed process leads to excellent enantiopurity both for etiracetam (ee>98 %) and mandelic acid (ee≈95 %) enantiomers
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
Research on chirality and chiral resolution experienced a long history, while studies on cocrystals ...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
International audienceDue to the chirality of life, the two enantiomers of chiral molecules can exhi...
In this paper, we identified a cocrystal conglomerate of mandelic acid using a drug compound as a co...
International audienceDue to the chirality of life, the two enantiomers of chiral molecules can exhi...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
Two enantiomers of the same chiral active pharmaceutical ingredients (APIs) often have different pha...
Two enantiomers of the same chiral active pharmaceutical ingredients (APIs) often have different pha...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
We tap into an unexplored area of preferential crystallization, being the first to develop simultane...
Research on chirality and chiral resolution experienced a long history, while studies on cocrystals ...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
International audienceDue to the chirality of life, the two enantiomers of chiral molecules can exhi...
In this paper, we identified a cocrystal conglomerate of mandelic acid using a drug compound as a co...
International audienceDue to the chirality of life, the two enantiomers of chiral molecules can exhi...
A large number of active pharmaceutical ingredients (API) are chiral. Most of them are synthesized a...
Two enantiomers of the same chiral active pharmaceutical ingredients (APIs) often have different pha...
Two enantiomers of the same chiral active pharmaceutical ingredients (APIs) often have different pha...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...
Generally, in chemical synthesis of chiral systems a racemic mixture is produced, that is a 50:50 mi...